Duration of Eliquis (Apixaban) for DVT Treatment
For a patient with diagnosed DVT, the duration of Eliquis depends critically on whether the DVT was provoked or unprovoked, with initial treatment lasting at least 3 months, followed by extended therapy decisions based on bleeding risk and recurrence risk.
Initial Treatment Phase
All patients with proximal DVT require at least 3 months of anticoagulation 1. The FDA-approved Eliquis regimen is 2:
- 10 mg twice daily for 7 days
- Then 5 mg twice daily for the remainder of treatment
For isolated distal (calf) DVT, 3 months is sufficient and extended therapy is not recommended 3.
Decision Point at 3 Months: Provoked vs. Unprovoked
Provoked DVT (Surgery or Transient Risk Factor)
Stop anticoagulation at 3 months 1. This is a strong recommendation because:
- Surgery-provoked DVT has annual recurrence risk <1% after stopping 3
- The guidelines explicitly recommend 3 months over extended therapy for provoked events 1
Exception: For hormone-associated DVT in women who stop hormonal therapy, 3 months is sufficient 3.
Unprovoked Proximal DVT
Consider extended (indefinite) anticoagulation beyond 3 months 3. The decision algorithm:
Low or moderate bleeding risk: Suggest extended therapy 1
- Unprovoked DVT carries >5% annual recurrence risk 3
- This exceeds typical anticoagulation bleeding risk
High bleeding risk: Stop at 3 months 1
If continuing beyond 3 months: Switch to Eliquis 2.5 mg twice daily after completing at least 6 months of treatment 2
Extended Therapy Monitoring
Reassess continuation annually 1. At each assessment, re-evaluate:
- Bleeding risk changes
- Patient preference
- Ongoing cancer or other acquired risk factors
Special Populations
Cancer-Associated DVT
Continue anticoagulation as long as cancer is active or under treatment 1, 4. While LMWH is preferred initially 1, recent evidence suggests apixaban 2.5 mg twice daily may be effective for extended therapy in cancer patients 5.
Recurrent Unprovoked DVT
Indefinite anticoagulation is strongly recommended 4. These patients have demonstrated high thrombotic risk.
Common Pitfalls
- Don't use 5 mg twice daily for extended therapy: The FDA label and trials support 2.5 mg twice daily after initial treatment 2
- Don't forget the 3-month minimum: Even provoked DVT requires full initial treatment 1
- Don't continue indefinitely without reassessment: Annual review is essential 1
- Distinguish proximal from distal DVT: Isolated calf DVT has different recurrence risk and doesn't warrant extended therapy 3
The strongest predictor of recurrence is whether the DVT was provoked or unprovoked 3. This single factor should drive your decision at the 3-month mark more than any other consideration.